Close Menu

Insurance companies and drugmakers are wrestling with the high cost of making and administering biologic drugs, says Avery Johnson on the Wall Street Journal's Health blog. These drugs can cost as much as $1.5 million a year, and patients and prescription plan payers are having a hard time affording them. On the other hand, Johnson adds, some of these drugs have "dramatic" results, sending sometimes-fatal diseases into remission.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.

The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.

23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.

In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.